Scotia Foscan NDA Amendment Could Get Treatment Benefit In Labeling
Executive Summary
An efficacy amendment to Scotia's Foscan NDA may allow the company to detail a treatment benefit in labeling for the head and neck cancer palliative agent, the firm indicated.
You may also be interested in...
Investigator/Firm Financial Ties May Trigger Heavier Scrutiny Of Data By FDA
Disclosure of financial arrangements between a clinical investigator and study sponsor will lead to a more stringent product review at FDA, Office of Drug Evaluation I Associate Director-Regulatory Affairs Linda Carter told the Food & Drug Law Institute.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials